From Wikipedia, the free encyclopedia
Chemical compound
Indacaterol
|
|
|
Trade names | Onbrez, Arcapta |
---|
AHFS/
Drugs.com |
International Drug Names |
---|
License data |
|
---|
Pregnancy category | |
---|
Routes of administration | Inhalation |
---|
ATC code | |
---|
|
Legal status |
|
---|
|
5-[2-[(5,6-Diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one
|
CAS Number | |
---|
PubChem
CID | |
---|
IUPHAR/BPS | |
---|
ChemSpider | |
---|
UNII | |
---|
KEGG | |
---|
ChEBI | |
---|
ChEMBL | |
---|
CompTox Dashboard (
EPA) | |
---|
ECHA InfoCard |
100.218.577
|
---|
|
Formula | C24H28N2O3 |
---|
Molar mass | 392.499 g·mol−1 |
---|
3D model (
JSmol) | |
---|
O=C4/C=C\c1c(c(O)ccc1[C@@H](O)CNC3Cc2cc(c(cc2C3)CC)CC)N4
|
InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1 YKey:QZZUEBNBZAPZLX-QFIPXVFZSA-N Y
|
NY
(what is this?)
(verify) |
Indacaterol is an ultra-
long-acting beta-adrenoceptor agonist
[5] developed by
Novartis. It needs to be taken only once a day,
[6] unlike the related drugs
formoterol and
salmeterol. It is licensed only for the treatment of
chronic obstructive pulmonary disease (COPD) (long-term data in patients with
asthma are thus far lacking). It is delivered as an aerosol formulation through a
dry powder inhaler.
Medical uses
A Cochrane review found benefit in lung function in people with COPD at least as good as that seen with twice-daily long-acting beta2-agonists.
[7]
History
It was approved by the
European Medicines Agency (EMA) under the brand name Onbrez Breezhaler on November 30, 2009,
[8] and by the
United States Food and Drug Administration (FDA), under the brand name Arcapta Neohaler, on July 1, 2011.
[9]
[10] In 2016, Novartis licensed its U.S. commercial rights for Arcapta Neohaler to
Sunovion Pharmaceuticals.
[11]
References
-
^
"Arcapta Neohaler (indacaterol) inhalation powder Initial U.S. Approval: 2011". DailyMed. 1 April 2020. Retrieved 14 June 2021.
-
^
"Onbrez Breezhaler EPAR".
European Medicines Agency (EMA). 17 September 2018. Retrieved 20 January 2021.
-
^
"Oslif Breezhaler EPAR".
European Medicines Agency (EMA). 17 September 2018. Retrieved 20 January 2021.
-
^
"Hirobriz Breezhaler EPAR".
European Medicines Agency (EMA). 17 September 2018. Retrieved 20 January 2021.
-
^ Cazzola M, Matera MG, Lötvall J (July 2005). "Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease". Expert Opin Investig Drugs. 14 (7): 775–83.
doi:
10.1517/13543784.14.7.775.
PMID
16022567.
S2CID
11930383.
-
^ Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A (May 2007).
"Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma". Eur. Respir. J. 29 (5): 871–8.
doi:
10.1183/09031936.00060006.
PMID
17251236.
-
^ Geake, James B (2015).
"Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for chronic obstructive pulmonary disease". Reviews. 1 (3): CD010139.
doi:
10.1002/14651858.CD010139.pub2.
PMC
6464646.
PMID
25575340.
-
^
European Public Assessment Report for Onbrez Breezhaler
Archived 2010-01-16 at the
Wayback Machine
-
^
"FDA approves Arcapta Neohaler to treat chronic obstructive pulmonary disease" (Press release). U.S. Food and Drug Administration. 2011-07-01. Archived from
the original on 2011-07-03. Retrieved 2011-07-02.
-
^
"Drug Approval Package: Arcapta Neohaler (indacaterol maleate) NDA #022383". U.S. Food and Drug Administration. 13 August 2013. Retrieved 14 June 2021.
-
^ Faulkner, Sarah (22 December 2016).
"Sunovion, Novartis ink licensing deal for inhaled COPD drugs". Drug Delivery Business.
|
---|
α1 | Agonists | |
---|
Antagonists |
-
Abanoquil
-
Ajmalicine
-
Alfuzosin
-
Anisodamine
-
Anisodine
-
Atiprosin
-
Atypical antipsychotics (e.g.,
brexpiprazole,
clozapine,
olanzapine,
quetiapine,
risperidone)
-
Benoxathian
-
Beta blockers (e.g.,
adimolol,
amosulalol,
arotinolol,
carvedilol,
eugenodilol,
labetalol)
-
Buflomedil
-
Bunazosin
-
Corynanthine
-
Dapiprazole
-
Domesticine
-
Doxazosin
-
Ergolines (e.g.,
acetergamine,
ergotamine,
dihydroergotamine,
lisuride,
nicergoline,
terguride)
-
Etoperidone
-
Fenspiride
-
Hydroxyzine
-
Indoramin
-
Ketanserin
-
L-765,314
-
mCPP
-
Mepiprazole
-
Metazosin
-
Monatepil
-
Moxisylyte
-
Naftopidil
-
Nantenine
-
Neldazosin
-
Niaprazine
-
Niguldipine
-
Pardoprunox
-
Pelanserin
-
Perlapine
-
Phendioxan
-
Phenoxybenzamine
-
Phentolamine
-
Phenylpiperazine
antidepressants (e.g.,
hydroxynefazodone,
nefazodone,
trazodone,
triazoledione)
-
Piperoxan
-
Prazosin
-
Quinazosin
-
Quinidine
-
Silodosin
-
Spegatrine
-
Spiperone
-
Talipexole
-
Tamsulosin
-
Terazosin
-
Tiodazosin
-
Tolazoline
-
Tetracyclic antidepressants (e.g.,
amoxapine,
maprotiline,
mianserin)
-
Tricyclic antidepressants (e.g.,
amitriptyline,
clomipramine,
doxepin,
imipramine,
trimipramine)
-
Trimazosin
-
Typical antipsychotics (e.g.,
chlorpromazine,
fluphenazine,
loxapine,
thioridazine)
-
Urapidil
-
WB-4101
-
Zolertine
|
---|
|
---|
α2 | Agonists | |
---|
Antagonists |
-
1-PP
-
Adimolol
-
Amesergide
-
Aptazapine
-
Atipamezole
-
Atypical antipsychotics (e.g.,
asenapine,
brexpiprazole,
clozapine,
lurasidone,
olanzapine,
paliperidone,
quetiapine,
risperidone,
zotepine)
-
Azapirones (e.g.,
buspirone,
gepirone,
ipsapirone,
tandospirone)
-
BRL-44408
-
Buflomedil
-
Cirazoline
-
Efaroxan
-
Esmirtazapine
-
Fenmetozole
-
Fluparoxan
-
Idazoxan
-
Ketanserin
-
Lisuride
-
mCPP
-
Mianserin
-
Mirtazapine
-
NAN-190
-
Pardoprunox
-
Phentolamine
-
Phenoxybenzamine
-
Piperoxan
-
Piribedil
-
Rauwolscine
-
Rotigotine
-
Setiptiline
-
Spegatrine
-
Spiroxatrine
-
Sunepitron
-
Terguride
-
Tolazoline
-
Typical antipsychotics (e.g.,
chlorpromazine,
fluphenazine,
loxapine,
thioridazine)
-
Yohimbine
|
---|
|
---|
β | |
---|
|